2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6340 Sex-based differences in toxicity and outcomes with intravenous decitabine and oral decitabine/cedazuridine in myeloid malignancies

Esther Albuquerque, PharmD, Taiylor Karasewski2, Qiuhong Zhao, MS3, Rachel Romestan4, Ann-Kathrin Eisfeld, MD5, Alice Scott Mims, MD6, Sharyn Baker, PharmD, PhD7, Allyson Waller, PharmD, BCOP8, Shivani Handa, MD9
1 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
4 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
8 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
9 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Background: Decitabine is a hypomethylating agent for treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Treatment-related cytopenias frequently result in dose modifications, cycle delays, infection, and bleeding complications. Retrospective studies have suggested inferior outcomes with decitabine in male compared with female patients (DeZern et al, 2017) potentially because higher cytidine deaminase (CDA) activity in males reduces cytidine-analogue exposure (Mahfouz et al, 2013). Conversely, greater exposure in females could increase toxicity, however this remains unknown. Oral decitabine/cedazuridine (DEC-C) includes the CDA inhibitor cedazuridine and may attenuate sex-associated differences. Therefore, we aimed to evaluate sex-based differences in hematological toxicity and outcomes among patients receiving intravenous decitabine (DAC) or DEC-C.  

Methods: This single-center retrospective cohort study evaluated adults with MDS, MDS/myeloproliferative neoplasm (MPN) overlap syndromes, or AML who received ≥1 cycle of single-agent DAC or DEC-C from January 2011 to December 2025. The primary outcome was to compare sex differences in hematologic toxicity incidence and severity assessed by the duration of grade 4 neutropenia/ thrombocytopenia (TCP), cycle delays, dose modifications, hospitalization for febrile neutropenia (FN) or bleeding, and treatment discontinuation due to toxicity. Secondary outcomes included response evaluation assessed using disease-specific consensus criteria, and overall survival (OS). Results were stratified by oral vs IV decitabine formulation. Patient characteristics, toxicity profiles and best responses were compared between males and females using the Mann-Whitney test or student’s T test or Fisher’s exact per data type. OS was calculated from the first dose of decitabine to date of death censoring those alive at the date of last follow up. OS was estimated using the Kaplan-Meier method and compared between sexes using the log-rank test. 

Results: Among 114 patients, 69 (60.5%) were male and 45 (39.5%) were female; 60 received DAC and 54 received DEC-C. Median age was 69 years, 75.4% had MDS, and 77.2% had an ECOG performance status of 0–1. Male patients more frequently received decitabine as second- or later-line therapy. Patients received an average of 4 cycles (SD, 4).   

Among DAC recipients, mean cycle length was significantly longer in females than males—37.6 days (SD, 4.3) vs 33.0 days (SD, 5.4; p=.04)—whereas no difference was observed with DEC-C: 39.2 days (SD, 12.3) vs 38.7 days (SD, 10.1; p=.87). The mean duration of grade 4 neutropenia did not differ between females and males—12.3 days (SD, 13.8) vs 13.3 days (SD, 9.8) per cycle, respectively (p=.66)—nor did the duration of grade 4 TCP: 8.6 days (SD, 9.9) vs 10.8 days (SD, 10.8; p=.29) and was not impacted by formulation. The incidence of FN-related admissions was similar between sexes. However, bleeding-related hospitalizations were more frequent in females (11.1% vs 1.4%; p=.02), with one being for vaginal bleeding. Due to low incidence, complications were not stratified by formulation. Total treatment duration and toxicity/intolerance-related discontinuation rates were similar between sexes for DAC and DEC-C. A greater proportion of females required ≥1 dose modification either as dose strength reduction, decrease in treatment duration or intentional increase in inter-cycle interval (83.3% vs 54.5%, p=0.02).

Response rates and OS did not differ between sexes. Median OS was poor across cohorts; 8.0 months (95% CI, 6.1–10.1) in males and 7.6 months (95% CI, 5.0–16.5) in females (p=.19). 

Conclusion: Female patients treated with decitabine had longer cycle delays and more frequent dose modifications. Notably, sex-based difference in cycle length was only observed with DAC and not DEC-C.  Bleeding-related hospitalization was more frequent in females but was based on few events. While these findings suggest some differences in tolerability between sexes, we did not observe any meaningful differences in duration of severe cytopenias or rates of discontinuation due to intolerance/toxicity. Unlike prior studies, we could not detect differences in response and survival outcomes perhaps due to limited sample size and inclusion of a heterogeneous cohort of MDS, MDS/MPN and AML patients. Overall, these preliminary results warrant validation in a larger, multicenter cohort with disease-specific analyses.

Esther Albuquerque, PharmD: No relevant conflicts of interest to declare.